Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion. EPI results due to a number of conditions such as cystic fibrosis, cytomegalovirus infection, pancreatic cancer, chronic pancreatitis, and HIV/AIDS. In the past few years, the vast rise in incidence of causative conditions have driven the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2748
According to the report, the global EPI therapeutics and diagnostics market was valued at US$3,397.5 mn in 2016 and is projected to reach US$6,414.4 mn by 2025, expanding at a CAGR of 7.2% from 2017 to 2025.
North America to Remain Dominant Regional Market
Of the key diagnostics tests used for diagnosing EPI, including computerized tomography (CT) scanning, magnetic resonance imaging (MRI), endoscopic ultra-sonography (EUS), and blood tests, the segment of CT scanning presently accounts for the dominant share in terms of revenue contribution to the global market. The segment is likely to remain the most in-demand modality for EPI diagnosis in the years to come, albeit lose some grounds owing to the easy availability of other more sensitive techniques such as MRI.
Geographically, the North America market accounts for a significant share in the overall market owing to the large patient pool and a rising prevalence of cystic fibrosis and diabetes. The region is likely to remain the top contributor to the global market in terms of diagnostics technologies, new drugs, and revenue.
Rise in Prevalence of Diabetes and Cystic Fibrosis Raises Potential Rate of Prevalence of EPI
One of the key factors contributing to the positive growth prospects of the global EPI therapeutics and diagnostics market presently is the astronomical rise in the number of people suffering from diabetes. Diabetes is known to be the key factor leading to an increased tendency of patients contracting cystic fibrosis and chronic pancreatitis, the two key factors that lead to EPI. According to the American Diabetes Association, the world will have nearly 366 mn diabetics by 2030.
Furthermore, studies show that nearly 90% of the people with cystic fibrosis end up having EPI. A high number of people suffering from chronic pancreatitis also develop EPI. According the Cystic Fibrosis Foundation, nearly 30,000 people in the U.S. alone and around 70,000 across the globe have cystic fibrosis. Nearly 1,000 new cases of the condition are diagnosed each year in the U.S. Owing to the alarming increase in the prevalence of cystic fibrosis, the risk of EPI also increases substantially.